Aileron Therapeutics | LinkedIn (original) (raw)

``

Biotechnology Research

Boston, MA 7,436 followers

Developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions.

About us

Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Boston, MA

Type

Public Company

Founded

2005

Specialties

Drug Development, Stapled Peptides, Biopharmaceuticals, Chemistry, Chemoprotection, Myelopreservation, Chemotherapy, and Supportive Care

Locations

Employees at Aileron Therapeutics

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding